Therapeutic effect of Qingyi decoction in severe acute pancreatitis-induced intestinal barrier injury

Figure 1 Pathologic changes in the pancreatic and intestinal tissues of the experimental model groups. Pancreatic tissue in A: Control; B: Severe acute pancreatitis (SAP); C: SAP treated with Qingyi decoction (QYT); D: SAP treated with dexamethasone (DEX); and E: SAP treated with verapamil (VER) rats. Intestinal tissue in F: Control; G: SAP; H: QYT-treated); I: DEX-treated; and J: VER-treated rats (hematoxylin and eosin, 100 ×).

Figure 2 Intestinal epithelial cell apoptosis of the experimental model groups. Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling assay in A: Control; B: Severe acute pancreatitis (SAP); C: SAP treated with Qingyi decoction; D: SAP treated with dexamethasone; E: SAP treated with verapamil rats (200 ×).

Figure 3 Electrophoresis micrographs of secreted phospholipase A₂ and β-actin mRNA quantitative PCR products. Electrophoresis micrograph of A: sPLA₂ mRNA (283 bp); and B: β-actin (as internal control; 531 bp); C: Gray value ratio of sPLA₂ to β-actin mRNA expression. ^aP < 0.05 vs SAP; ^bP < 0.01 vs CON. CON: Control; DEX: Dexamethasone; M1: 1000 bp-marker; M2: 2000 bp-marker; QYT: Qingyi decoction; SAP: Severe acute pancreatitis; VER: Verapamil.

Figure 4 Secreted phospholipase A₂ protein expression in intestinal tissue. A: Western blotting for intestinal tissue sPLA₂ protein expression (β-actin was used as the loading control); B: Gray value ratio of sPLA₂ to β-actin protein expression. ^aP < 0.05 vs SAP; ^bP < 0.01 vs CON. CON: Control; DEX: Dexamethasone; QYT: Qingyi decoction; SAP: Severe acute pancreatitis; VER: Verapamil.